OncLive TV

Bogdana Schmidt, MD, MPH, details the emergence of novel treatment delivery methods in bladder cancer.

Paolo Tarantino, MD, discusses the expanding role of T-DXd in HER2-positive breast cancer.

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

Jorge A. Garcia, MD, discusses the clinical impact of the FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC.

Joseph C. Murray, MD, PhD, discusses the safety profiles of encorafenib/binimetinib and dabrafenib/trametinib in patients with BRAF V600E–mutant NSCLC.

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

Nusrat Jahan, MD, explains the role of T-DXd as the first cytotoxic therapy in patients with HR-positive/HER2-low or -ultralow breast cancer.

Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.

Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.

Matthew Wagar, MD, discusses the addition of T-DXd to the HER2-positive endometrial cancer treatment paradigm.

Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.

Nataliya Uboha, MD, PhD, discusses how biomarkers help guide treatment decision-making in esophageal adenocarcinoma.

Nerea Lopetegui-Lia, MD, elaborates on several highly anticipated studies evaluating ADCs that could shape the future TNBC treatment paradigm.

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

Rami Komrokji, MD, discusses several trials that supported the FDA approval of luspatercept for the treatment of patients with MDS with anemia.

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Brad S. Kahl, MD, details the outcomes of bortezomib plus bendamustine/rituximab in patients with mantle cell lymphoma.

Erica Maria Pimenta, MD, PhD, discusses the future for evaluating tumor progression and immune evasion in soft tissue sarcomas.

Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.

Nataliya Mar, MD, discusses attempts to develop mechanisms for resensitizing prostate tumors to ARPI rechallenge.

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

Aaron Gerds, MD, details the prevalence of anemia in patients with low- to intermediate-1–risk myelofibrosis.

Van Karlyle Morris, MD, discusses the efficacy of nivolumab plus ipilimumab according to stratification factors in dMMR/MSI-H mCRC.

Bogdana Schmidt, MD, MPH, highlights FDA approved bladder-sparing therapies for patients with BCG-refractory non–muscle-invasive bladder cancer.

James J. Harding, MD, discusses efficacy data with nivolumab plus ipilimumab that led to this regimen’s FDA approval for unresectable or metastatic hepatocellular carcinoma

Jonathan Strosberg, MD, discusses how the phase 2 DAREON-5 trial could address questions about the use of DLL3/CD3-targeted agents in SCLC and other NECs.

Juan Carlos Hernández-Boluda, MD, PhD, details the advantages of EBMT machine learning vs existing transplant risk assessment tools in myelofibrosis.

Justin Moser, MD, discusses key considerations for second-line treatment selection for patients with melanoma who have progressed on PD-1 inhibitors.